Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Patients With Mantle Cell (MCL), T-cell (TCL), and Diffuse B-Cell Lymphoma (DLBCL)

Trial Profile

Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Patients With Mantle Cell (MCL), T-cell (TCL), and Diffuse B-Cell Lymphoma (DLBCL)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top